Mary Wilson
Well-known member
Feb 4, 2022 8:05am
by Nick Paul Taylor
Pfizer is taking its Valneva-partnered Lyme disease vaccine into phase 3. With midphase data supporting a three-dose series, the allies plan to kick off a phase 3 clinical trial of the regimen in the third quarter.
... Pfizer’s three-dose regimen gives VLA15 the second dose at two months and the third at six months. The two-dose regimen misses out the shot at two months. As the phase 2 trial found there is value in adding the third dose, the partners plan to test that regimen in the late-phase study.
... The number of reported cases of Lyme disease in the U.S. has tripled since the late 1990s, potentially because of changes in land use that have brought more humans into close contact with tick hosts. Whatever the cause, the rise has led the Centers for Disease Control and Prevention to say new tools for preventing tick-borne diseases are needed urgently.
https://www.fiercebiotech.com/biote...es-to-phase-3-after-booster-shown-to-increase
by Nick Paul Taylor
Pfizer is taking its Valneva-partnered Lyme disease vaccine into phase 3. With midphase data supporting a three-dose series, the allies plan to kick off a phase 3 clinical trial of the regimen in the third quarter.
... Pfizer’s three-dose regimen gives VLA15 the second dose at two months and the third at six months. The two-dose regimen misses out the shot at two months. As the phase 2 trial found there is value in adding the third dose, the partners plan to test that regimen in the late-phase study.
... The number of reported cases of Lyme disease in the U.S. has tripled since the late 1990s, potentially because of changes in land use that have brought more humans into close contact with tick hosts. Whatever the cause, the rise has led the Centers for Disease Control and Prevention to say new tools for preventing tick-borne diseases are needed urgently.
https://www.fiercebiotech.com/biote...es-to-phase-3-after-booster-shown-to-increase
